請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66465
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林淑文 | |
dc.contributor.author | Yun-Ting He | en |
dc.contributor.author | 賀筠婷 | zh_TW |
dc.date.accessioned | 2021-06-17T00:37:10Z | - |
dc.date.available | 2017-03-02 | |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-02-01 | |
dc.identifier.citation | 1. Prod Info VFEND(R) IV injection , oral tablets, suspension, US Food and Drug Administration. In; 2008.
2. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2. 3. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. 4. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 5. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007;51:137-43. 6. Hyland R, Jones B, Smith D. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug metabolism and disposition 2003;31:540-7. 7. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009;49:196-204. 8. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 2009;68:906-15. 9. Yang JC, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opinion on Drug Metabolism & Toxicology 2010;6:29-41. 10. Xie HG. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population. Life Sci 2000;66:PL175-PL81. 11. Liou YH, Lin CT, Wu YJ, Wu LS. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. J Hum Genet 2006;51:857-63. 12. Lee S, Kim BH, Nam WS, et al. Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. J Clin Pharmacol 2011:1-9. 13. Ikeda Y UK, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587-8. 14. Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009;34:91-4. 15. Kim SH, Yim DS, Choi SM, et al. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Int J Infect Dis 2011:753-8. 16. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. The Journal of Clinical Pharmacology 2006;46:235-43. 17. Ueda K, Nannya Y, Kumano K, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592-9. 18. Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 2003;37:420-32. 19. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 1997;41:2492-6. 20. Paul Balenger CN, Rutilio Fratti,Homayoon Sanati, Mahmoud Ghannoum. Voriconazole inhibits the growth and alters the morphology of fluconazole- susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997:1840-2. 21. ELIAS K. MANAVATHU JLC, AND PRANATHARTHI H. CHANDRASEKAR. organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998:3018-21. 22. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63. 23. Mavridou E, Bruggemann RJM, Melchers WJG, Verweij PE, Mouton JW. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2010;54:4758-64. 24. ARTHUR L. BARRY SDB. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996:1948-9. 25. Manuel Cuenca-Estrella BR-D, Joaquin V. Martinez-Suarez, Araceli Monzon and Juan L. Rodriguez-Tudela. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999:149-51. 26. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004;54:1051-6. 27. Diekema D, Messer S, Hollis R, Jones R, Pfaller M. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6. 28. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole. Br J Clin Pharmacol 2003;56:17-23. 29. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009;61:541-58. 30. Ballesta S, Garcia I, Perea EJ, Pascual A. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J Antimicrob Chemother 2005;55:785-7. 31. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-32. 32. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997;97:662-5. 33. Joseph Meletiadis SC, Tomas J Walsh. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 2008;9:561-84. 34. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84. 35. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen M, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002;46:2546-53. 36. Healthcare T. MicromedexR Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically. In. 37. Gerd Mikus, Ina Maria Scholz, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. pharmacogenomics 2011;12:861–72. 38. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. 39. 黃玉婷碩士論文. 侵入性黴菌感染使用voriconazole之療劑監測研究 ; 2011:1-122. 40. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004;10:73-90. 41. Wermers RA, Cooper K, Razonable RR, et al. Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy. Clin Infect Dis 2011;52:604-11. 42. Bartlett JG AP, Pham PA. . Diagnosis and Treatement of Infectious Diseases Johns Hopkins ABX Guide 2010 second edition: Jones & Bartlett Learing;Appendix III. In; 2010:842-4. 43. Kupfer A. Family study of a genetically determined deficiency of mephenytoin hydroxylation to p-hydroxymephenytoin in man. Pharmacologist 1979;21:173. 44. Wrighton S, Stevens J, Becker G, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993;306:240-5. 45. Goldstein J, Faletto M, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry (Mosc) 1994;33:1743-52. 46. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-58. 47. Ferguson RJ, De Morais SMF, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-61. 48. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009;65:281-5. 49. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 2010;69:222-30. 50. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants&ast. Clin Pharmacol Ther 2006;79:103-13. 51. Miura J, Obua C, Abbo C, Kaneko S, Tateishi T. Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 2009;65:319-20. 52. Garcia-Barcelo M, Chow LY, Chiu HFK, et al. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19* 4. Clin Chem 1999;45:2273-4. 53. Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19* 17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008;65:437-9. 54. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19* 17 discovery: the case of Greece. Pharmacogenomics 2009;10:43-9. 55. Pedersen RS, Brasch-Andersen C, Sim SC, et al. Linkage disequilibrium between the CYP2C19* 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol 2010;66:1199-205. 56. 陳明杰碩士論文. 在花蓮不同族群中cytochrome P450 2C19(CYP2C19)主要基因型分布; 2005:1-67. 57. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the Incidence of the CYP2C19Polymorphism Affecting the S-Mephenytoin Phenotype in Chinese Han and Bai Populations and Identification of a New RareCYP2C19 Mutant Allele. J Pharmacol Exp Ther 1997;281:604-9. 58. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64. 59. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996;6:547-51. 60. Sviri S, Shpizen S, Leitersdorf E, Levy M, Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population&ast. Clin Pharmacol Ther 1999;65:275-82. 61. Bertilsson L LY, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97. 62. Bathum L, Andersen-Ranberg K, Boldsen J, Brosen K, Jeune B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998;54:427-30. 63. Ruas JL, Lechner MC. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics 1997;7:333-5. 64. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe&ast. Clin Pharmacol Ther 1995;57:656-61. 65. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996;6:521-6. 66. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype&ast. Clin Pharmacol Ther 1996;60:138-44. 67. Purkins L, Wood N, Ghahramani P, Kleinermans D, Layton G, Nichols D. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. Br J Clin Pharmacol 2003;56:30-6. 68. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir&ast. Clin Pharmacol Ther 2006;80:126-35. 69. Levin MD, den Hollander JG, van der Holt B, et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. J Antimicrob Chemother 2007;60:1104-7. 70. Berke EM, Morden NE. Medical management of obesity. Am Fam Physician 2000;62:419-26. 71. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011;55:2601-5. 72. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007;51:137. 73. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Current protocols in human genetics / editorial board, Jonathan L Haines [et al] 2009;Chapter 2:1-18. 74. Pauw BD, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21. 75. Naranjo C, Busto U, Sellers E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. 76. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World journal of gastroenterology: WJG 2008;14:6774-85. 77. GarcIA-CortES M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-9. 78. Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30. 79. DS T, ed. Drug Interaction Facts TM; 2010. 80. Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009;169:505-14. 81. Lui YYN, Chik KW, Chiu RWK, Ho CY, Lam CWK, Lo Y. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002;48:421-7. 82. Iwamoto T, Monma F, Fujieda A, Nakatani K, Katayama N, Okuda M. Hepatic Drug Interaction Between Tacrolimus and Lansoprazole in a Bone Marrow Transplant Patient Receiving Voriconazole and Harboring CYP2C19 and CYP3A5 Heterozygous Mutations. Clin Ther 2011:1077-80. 83. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009;53:935-44. 84. 曾郁茹碩士論文. 某醫學中心Voriconazole使用現狀之回溯性研究; 2010:1-145. 85. Kaneko A, Kaneko O, Taleo G, Bjorkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997;349:921. 86. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003;35:99-106. 87. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population&ast. Clin Pharmacol Ther 1996;60:661-6. 88. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole–a novel wide‐spectrum antifungal agent. Br J Clin Pharmacol 2003;56:2-9. 89. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori&ast. Clin Pharmacol Ther 1999;66:528-34. 90. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71. 91. Den Hollander JG, Van Arkel C, Rijnders BJ, Lugtenburg PJ, De Marie S, Levin MD. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006;57:1248. 92. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002;35:1273-5. 93. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009;50:1-23. 94. Bourcier K, Hyland R, Kempshall S, et al. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole-and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug metabolism and disposition 2010;38:923-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66465 | - |
dc.description.abstract | 背景:
Voriconazole為第二代廣效型抗黴菌藥品,為治療侵入性麴菌感染(Invasive aspergillosis)的一線用藥,具有飽和型非線性代謝的特性,主要經由肝臟酵素代謝,其中又以CYP2C19扮演最重要的角色。CYP2C19具有基因多型性,亞洲約有8.00 %~23.10 %為慢代謝者(poor metabolizer, PMs),不同的基因型使藥品血中濃度在個體間變異性大,PM的藥品血中濃度約是快代謝者(extensive metabolizer, EMs)的4~5倍,增加濃度相關的不良反應(adverse drug reaction, ADR)如肝毒性、幻覺與視覺干擾發生的風險。目前尚未有研究針對臺灣病人族群使用voriconazole時,不同CYP2C19基因型對藥品濃度或ADR造成的影響,因此本研究採前瞻性收案,研究不同CYP2C19基因型與voriconazole藥品濃度及ADR的相關性。 研究目的: 研究CYP2C19基因多型性與voriconazole血中濃度及與濃度相關ADRs間的相關性。 研究方法: 於2009年3月1日至2011年1月31日間,在臺大醫院與和信治癌醫院前瞻性收案門診或住院使用voriconazole的病人,病人了解並簽署同意書後納入研究分析。排除在進入研究前做過異體骨髓移植、CYP2C19基因型資料有缺漏、無藥品血中濃度或完全沒有穩定狀態藥品血中濃度、併用第一級顯著交互作用的藥品、治療過程中非使用一天兩次(BID或Q12H)的給藥模式之病人。 病人使用voriconazole 5~7天後達到穩定藥品血中濃度,即追蹤藥品谷濃度(trough concentration, Ctrough)及峰濃度(peak concentration, Cpeak)。使用高效能液相層析系統(HPLC)以UV偵測吸收波長來測定藥品濃度,並將自白血球中分離出的染色體,送至中央研究院國家基因體醫學研究中心進行iPLEX(Increased Plexing, Efficiency and Flexibility for MassARRAY System)基因型測定。 本研究紀錄收案病人基本資料、實驗室檢查值並觀察用藥期間是否有發生藥品不良反應(ADR),藥品不良反應以Naranjo scale評估與藥品的相關性,肝毒性方面另多用RUCAM scale評估,以評估判定確定(definite)、極有可能(highly probable)、極可能(probable)者為voriconazole相關ADR並納入分析。 統計方法使用Student’s t test、Mann-Whitney U test、χ2 test比較兩組樣本間的差異,使用Wilcoxon signed-rank test 比較三組樣本間的差異。以多元迴歸模式評估CYP2C19是否為影響藥品濃度的重要因子。 研究結果: 本研究收案127人,排除44位病人,一共83人納入分析,以血液腫瘤疾病為主(79.50 %),主要用來治療侵入性黴菌感染。83位病人中有31位(37.40 %)快代謝者(EM)、42位(50.60 %)中速代謝者(HEM)以及10位(12.00 %)慢代謝者(PM)。 為比較相同起始給藥頻次下,不同CYP2C19基因型的病人第一次測得voriconazole血中濃度的差別,在分析濃度與CYP2C19的相關性時,只分析75位使用一天兩次劑量且有第一次穩定狀態血中濃度的病人。本研究的Cpeak與Ctrough有很好的相關性(R2=0.91)。75位病人中有29位(38.70 %)EM、36位(48.00 %)HEM及10位(13.30 %)PM,CYP2C19基因型和藥品血中濃度沒有相關性。將病人依voriconazole使用途徑分組,75位中有49位(65.30 %)病人使用口服voriconazole,CYP2C19基因型會影響藥品濃度,其中HEM(3.87±2.41 mg/L)與PM(5.69±2.90 mg/L)的Ctrough顯著大於EM(2.51±2.04 mg/L), HEM的藥品濃度約為EM的1.54倍,PM約為EM的2.30倍,p-value分別為0.05與0.03;以dose-adjusted Ctrough 也看到相同結果(p-value分別為0.03與0.04)。75位病人中有26位(34.60 %)使用靜脈注射劑型的病人,在這群病人中則看不出血中濃度的趨勢,PM病人甚至有較低的血中濃度,可能跟樣本數較少有關(N=26)。在濃度與CYP2C19基因型的迴歸分析中,發現口服病人群中,年齡與CYP2C19基因型可以預測25.70 %藥品濃度的變化。 本研究83位病人一共發生76件voriconazole相關ADR,其中最常見者為視覺干擾(42.10 %),其次為肝毒性(39.50 %)及幻覺(18.40 %)。CYP2C19基因型和任一ADR的發生沒有相關性,PM病人相較於HEM與EM病人有較高voriconazole相關ADR發生的趨勢。在肝毒性方面,CYP2C19基因型與voriconazole相關肝毒性的發生沒有顯著相關。在神經毒性如幻覺及視覺干擾方面,CYP2C19基因型和神經毒性的發生也沒有顯著相關。CYP2C19基因型和voriconazole相關ADR間沒有顯著相關,可能和本研究在追蹤病人的過程中,積極為病人調整voriconazole血中濃度使其落在療劑範圍(therapeutic range)之內有關。 結論: 本研究為第一個在使用口服與靜脈注射劑型voriconazole的病人,比較CYP2C19基因型與voriconazole血中濃度及不良反應間關係的研究。對於使用口服voriconazole的病人,CYP2C19基因型的變異會影響藥品濃度的變化,HEM與PM病人的平均Ctrough各約為EM病人的1.54及2.30倍,統計上有顯著差異。CYP2C19基因型的變異與不良反應的發生均沒有統計上顯著差異。 | zh_TW |
dc.description.abstract | Background:
Voriconazole is a second-generation broad-spectrum antifungal agent. It is used as the first line treatment for invasive aspergillosis. Voriconazole exhibit saturable nonliniear pharmacokinetics. It is metabolized by liver enzymes, mainly CYP2C19. CYP2C19 has genetic polymorphism. There are 8.00 % to 23.10 % poor metabolizers (PMs) in Asian population. Voriconazole blood concentration has large intraindividual and interindividual variation. It is reported that PMs have 4 to 5 times higher trough voriconazole concentration than extensive metabolizers (EMs) do, thus they may experience increased risk of concentration-dependent toxicity, such as liver toxicity, hallucination and visual disturbance. There are limited data of voriconazole trough concentration and adverse drug reactions (ADRs) in relation to CYP2C19 genetic polymorphism in Taiwan, therefore we performed a prospective study to investigate CYP2C19 genetic polymorphism and its relationship to voriconazole concentration and voriconazole-associated ADRs. Objective: CYP2C19 genetic polymorphism in relation to voriconazole concentration and concentration-dependent ADRs. Methods: This prospective study was held in National Taiwan University and Koo Foundation Sun Yat-Sen Cancer Center from March 1st in 2009 to Janurary 31st in 2011. Inpatients and outpatients who used voriconazole and signed the informed consent were included in this study. Patients who have had allogeneitic bone marrow transplantation prior to enrollment, did not have CYP2C19 genetic information, did not have voriconazole concentration or did not have steady state voriconazole concentration, co-administered significance rating 1 drug interaction drugs while testing voriconazole concentration, did not use twice daily(BID or Q12H) regimen were excluded. Steady state voriconazole plasma concentration (peak and trough) were drawn 5-7 days after initiating voriconazole. Voriconazole concentration were determined by high performance liquid chromatography and UV light. DNA samples were extracted from the patients’ white blood cell. iPLEX (Increased Plexing, Efficiency and Flexibility for MassARRAY System) was performed to dectect for genetic polymorphism. Patients’ demographic character, lab results and vori-associated ADRs were recorded. The Narajo scale was applied to evaluate the causality of the ADRs in relation to voriconazole use. In addition, RUCAM scale was applied to evaluate drug associated hepatotoxicity. Voriconazole associated ADRs were ADRs which were evaluated as “Definite”, “probable” in Naranjo scale or “highly probable”, “probable” in RUCAM scale. Voriconazole associated ADRs will be analysed for the relationship between CYP2C19 genetic polymorphism and ADRs. Student’s t test, Mann-Whitney U test, and χ2 test were used to compare the differences between two groups. Wilcoxon signed-rank test was used to compare the differences among three groups. Multiple regression was used to investigate whether CYP2C19 genetic polymorphism is a main factor for predicting voriconazole plasma concentration. Results: A total of 127 patients were enrolled, but only 83 patients were included in the analysis. Most of them had hematological disease (79.50 %). Voriconazole was used for invasive fungal infections. Thirty one patients (37.40 %) were CYP2C19 EMs, 42 patients (50.60 %) were CYP2C19 heterozygous extensive metabolizers (HEMs) and 10 patients (12.00 %) were CYP2C19 PMs in the patient population. In the study of CYP2C19 polymorphism in relation to voriconazole concentration, only the first steadt state voriconazole concentration was included for comparing the voriconazole concentration under same initial dosing frequency. There were 75 patients meeting the criteria. There was a good correlation between trough concentrations and peak concentrations in this study. Among total 75 patients, there were 29 (65.30%) EMs, 36 (48.00%) HEMs and 10 (13.30%) PMs. There was not a correlation between CYP2C19 polymorphism and voriconazole concentration. There were 49 (65.30 %) patients took oral form voriconazole, the polymorphism of CYP2C19 made correlate significantly with variation of voriconazole plasma concentrations. HEMs (3.87 ± 2.41 mg/L) and PMs (5.69 ± 2.90 mg/L) had higher trough concentrations than EMs (2.51 ± 2.04 mg/L), with p-values of 0.05 and 0.03, respectively. If dose-adjusted trough was used instead, similar results were found, with p-values of 0.03 and 0.04, respectively. Twenty-six patients received intraveneous (IV) form of voriconazole. There was no relationship between trough (dose-adjusted trough) and CYP2C19 polymorphism in patients who use IV form of voriconazole. PMs had unexpected lower drug concentrations compared to EMs and HEMs. This result may be due to small sample size of patients who used IV form of voriconazole (N=26). In the multiple regression model, age and CYP2C19 polymorphism can predict 25.70% of the change of voriconazole trough concentration in patients who were on oral form of voriconazole. There were 76 voriconazole associated (vori-associated) ADRs in 83 patients. The most common ADRs of voriconaozle are visual disturbance (42.10 %), hallucination (18.40 %) and hepatotoxicity (39.50 %). There was no correlation between CYP2C19 polymorphism and vori-associated ADRs, however PM patients seemed to have higher ratio of vori-associated ADRs. Take a deep look to each vori-associated ADRs. There was no correlation between CYP2C19 polymorphism and vori-associated hepatotoxicity、vori-associated hallucination and vori-associated visual disturbance respectively. Conclusion: In patients who used oral form voriconazole, voriconazole trough concentrations of HEMs and PMs were 1.54 and 2.30 times higher than Ems, respectively. PMs had higher risk of having voriconazole associated ADRs. However, there was no correlation between CYP2C19 and vori-associated ADRs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:37:10Z (GMT). No. of bitstreams: 1 ntu-101-R98451008-1.pdf: 2016781 bytes, checksum: e34999994f2baed68816957ca044e35b (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 中文摘要 ii
Abstract v 目錄 ix 圖表目錄 xi 縮寫表 xiv 第一章 緒論 1 第二章 文獻探討 2 2.1 Voriconazole簡介 2 2.1.1藥理與藥效作用 2 2.1.2 藥品動態學特性 4 2.1.3 適應症與劑量 8 2.1.4療劑範圍 9 2.1.5不良反應 10 2.1.6藥品交互作用 11 2.2 CYP2C19與臺灣地區CYP2C19基因型分布 17 2.3 CYP2C19與voriconazole藥品濃度的相關性 21 2.4 CYP2C19與voriconazole藥品不良反應的相關性 24 第三章 研究目的 25 第四章研究方法 26 4.1 研究架構 26 4.2 研究對象、地點 27 4.3 納入條件及排除條件 27 4.4相關資料收集 27 4.4.1受試者基本資料 27 4.4.2 受試者之肝腎功能 28 4.4.3 Voriconazole給藥與抽血時間紀錄 28 4.4.4 濃度 29 4.5濃度測量方法 29 4.6 抽取DNA 30 4.7 SNP測定與Primer設計 30 4.8侵入性黴菌感染適應症 34 4.9 藥品不良反應評估 38 4.10 藥品交互作用對CYP2C19的影響 42 4.11 統計方法 44 第五章 研究結果 45 5.1 收案病人流程 45 5.2.病人基本資料 47 5.3 Voriconazole濃度與基因型的相關性 62 5.4不良反應評估 67 5.5血中谷濃度多元迴歸分析 78 第六章 討論 81 6.1病人族群 81 6.2 CYP2C19基因型分布 82 6.3藥品濃度與CYP2C19基因型分析 83 6.4不良反應與CYP2C19基因型分析 87 6.5 異體骨髓移植前後基因型的差異 90 6.6研究限制 91 6.7未來展望 91 第七章 結論 92 參考文獻 93 | |
dc.language.iso | zh-TW | |
dc.title | CYP2C19基因多型性與Voriconazole藥品血中濃度與不良反應之關聯性研究 | zh_TW |
dc.title | CYP2C19 Genetic Polymorphisms in Relation to Voriconazole Concentration and Adverse Drug Reactions | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 沈麗娟 | |
dc.contributor.oralexamcommittee | 張上淳,陳宜君,林慧玲 | |
dc.subject.keyword | voriconazole,CYP2C19,血中濃度,肝毒性,幻覺,視覺干擾, | zh_TW |
dc.subject.keyword | voriconazole,CYP2C19,voriconazole concentration,hepatotoxicity,hallucination,visual disturbance, | en |
dc.relation.page | 103 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-02-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.97 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。